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Changes in MicroRNA Expression Contribute to
Pancreatic b-Cell Dysfunction in Prediabetic NOD Mice
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During the initial phases of type 1 diabetes, pancreatic islets are
invaded by immune cells, exposing b-cells to proinﬂammatory
cytokines. This unfavorable environment results in gene expres-
sion modiﬁcations leading to loss of b-cell functions. To study the
contribution of microRNAs (miRNAs) in this process, we used
microarray analysis to search for changes in miRNA expression
in prediabetic NOD mice islets. We found that the levels of miR-
29a/b/c increased in islets of NOD mice during the phases pre-
ceding diabetes manifestation and in isolated mouse and human
islets exposed to proinﬂammatory cytokines. Overexpression of
miR-29a/b/c in MIN6 and dissociated islet cells led to impairment
in glucose-induced insulin secretion. Defective insulin release
was associated with diminished expression of the transcription
factor Onecut2, and a consequent rise of granuphilin, an inhibitor
of b-cell exocytosis. Overexpression of miR-29a/b/c also promoted
apoptosis by decreasing the level of the antiapoptotic protein
Mcl1. Indeed, a decoy molecule selectively masking the miR-29
binding site on Mcl1 mRNA protected insulin-secreting cells from
apoptosis triggered by miR-29 or cytokines. Taken together, our
ﬁndings suggest that changes in the level of miR-29 family mem-
bers contribute to cytokine-mediated b-cell dysfunction occurring
during the initial phases of type 1 diabetes. Diabetes 61:1742–
1751, 2012
Aﬁne control of the amount of insulin releasedby pancreatic b-cells is essential to maintainappropriate blood glucose levels. Type 1 dia-betes is an autoimmune disease characterized
by progressive destruction of pancreatic b-cells that, if un-
treated, leads to life-threatening alterations of blood glucose
homeostasis and body metabolism. During the initial phases
of the disease, b-cells are chronically exposed to elevated
concentrations of cytokines released by the immune cells
that inﬁltrate the islets of Langerhans and by endocrine
cells themselves (1). This inﬂammatory environment has
a deleterious impact on specialized b-cell functions,
resulting in impaired insulin biosynthesis and secretion
and in b-cell loss by apoptosis in the long term. A de-
tailed understanding of the molecular events elicited by
proinﬂammatory cytokines, and responsible for b-cell
dysfunction, is essential to pave the way to the de-
velopment of new approaches for preventing and treat-
ing type 1 diabetes.
Global microarray proﬁling of b-cells chronically exposed
to cytokines revealed that these inﬂammatory mediators
induce major changes in gene expression, causing severe
impairment in key signaling pathways (1,2). So far, most of
the studies investigating the mechanisms underlying the
changes in gene expression that occur in the presence of
cytokines focused on transcription factors such as nuclear
factor kB (NFkB) (3). However, there is growing evidence
that another class of gene regulators, called microRNAs
(miRNAs) play an important role in the control of b-cell
functions, under both control and physiopathologic con-
ditions (4–14). These short, noncoding RNA molecules bind
to speciﬁc sequences of the 39-untranslated region (39UTR)
of target mRNAs, causing message destabilization and/or
translational inhibition (15,16). We recently reported that
prolonged exposure of b-cells to proinﬂammatory cytokines
leads to the induction of three miRNAs—miR-21, miR-34a,
and miR-146—resulting in defective insulin secretion and
apoptosis (11). We found that the level of these miRNAs is
increased in the islets of NOD mice, a well characterized
type 1 diabetes model (11), suggesting a potential contri-
bution of these small RNA molecules to b-cell failure during
the instauration of the disease.
In this study, we used microarray proﬁling to search for
global changes in miRNA expression in pancreatic islets of
prediabetic NOD mice. We found that, in addition to the
three miRNAs mentioned above, the development of type 1
diabetes in NOD mice is associated with a strong induction
in islet cells of the members of the miR-29 family. Studies
performed in b-cell lines and dissociated islet cells revealed
that overexpression of miR-29 to levels comparable to those
observed in NOD mice leads to defective glucose-induced
insulin secretion and promotes apoptosis, suggesting a con-
tribution of this family of miRNAs to the initial phases of
type 1 diabetes.
RESEARCH DESIGN AND METHODS
Chemicals. Interleukin-1b (IL-1b) was purchased from Sigma (Buchs,
Switzerland), recombinant mouse interferon-g (IFN-g) from R&D Systems
(Minneapolis, MN), and tumor necrosis factor-a (TNF-a) from Alexis Cor-
poration (Lausen, Switzerland). Hoechst dye 33342 was obtained from Invitrogen
(Basel, Switzerland).
Isolation and culture of pancreatic islets and MIN6 cells. The insulin-
secreting cell line MIN6 clone B1 (17) was cultured at a density of 1.5 3 105
cells/cm2 in DMEM-Glutamax medium (Invitrogen, Carlsbad, CA) supplemented
with 15% FCS, 50 IU/mL penicillin, 50 mg/mL streptomycin, and 70 mmol/L
b-mercaptoethanol.
Mouse pancreatic islets were isolated by collagenase digestion (18) from
female NOD or C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME). After
isolation, NOD mice islets were immediately processed for RNA puriﬁca-
tion. C57BL/6 mouse islet cells were dissociated by exposing the islets
for 6 min to a Ca2+-free buffer containing 116 mmol/L NaCl, 24 mmol/L
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NaHCO3, 5 mmol/L KCL, 1 mmol/L MgCl2, 20 mmol/L HEPES, and 0.1% trypsin
at 37°C (18). The dispersed cells were then seeded at a density of 5.5 3 104
cells/cm2.
Human pancreatic islets were provided by the Cell Isolation and Trans-
plantation Center at the University of Geneva, School of Medicine, thanks to the
European Consortium for Islet Transplantation “islets for research” distribu-
tion program sponsored by the Juvenile Diabetes Research Foundation. In the
current study, we used islet preparations from six donors (ﬁve women and one
man) who were 56 6 6 years old and had a BMI of 22 6 4 kg/m2. The purity of
the islet preparations was 79 6 10% and contained 51 6 7% insulin-positive
cells.
After isolation, the islets were cultured in CMRL medium (Invitrogen,
Carlsbad, CA) supplemented with 10% FCS, 100 IU/mL penicillin, 100 mg/mL
streptomycin, 2 mmol/L L-glutamine, and 250 mmol/L HEPES. Islet cell mono-
layers were prepared by treating the islets for 7 to 9 min with trypsin (5 mg/mL)
at 37°C. Trypsinization was terminated by adding serum-containing culture
medium. The cells were seeded at a density of 5.5 3 104 cells/cm2.
Measurement of miRNA expression. For microarray analysis, total RNA of
islets from 4- and 8-week-old NODmice was extracted using the miRNeasy Mini
Kit (Qiagen, Hilden, Germany). Global miRNA proﬁling was performed by the
DNA Array Facility of our institution using Agilent Technologies miRNA Gene
Microarrays. The analysis permitted to determine the level of all mousemiRNAs
available on the Sanger miRBase version 9.1. Quantitative assessment of the
level of individual miRNAs was carried out by performing a Universal RT
reaction with locked nucleic acid (LNA)-enhanced PCR primers, followed by
real-time PCR (Exiqon, Vedbaek, Denmark). The results were normalized
using cDNAs ampliﬁed with U6 primers in the same samples. This small nu-
clear RNA is not affected by cytokine treatment. Similar results were obtained
when the data were normalized to miR-7.
Localization of miRNAs. To assess whether miRNAs are expressed by islet
cells and/or by the intraislet immune cells, islets of 13-week-old female NOD
mice were isolated by collagenase digestion and incubated for 24 h to allow
spontaneous extrusion of the lymphocytes (19,20). Moreover, cryosections
of pancreas of 4-, 8-, and 13-week-old NOD male mice were ﬁxed in 4%
FIG. 1. The expression of the members of the miR-29 family increases with age in the pancreatic islets of NOD mice. A: Pancreatic islets were
isolated from female NOD mice of different ages. Only animals displaying blood glucose levels within the normal range were included in the study.
The levels of miR-29a/b/c were measured by qRT-PCR, expressed as percentage of U6 expression and are shown as mean 6 SEM of three to six
independent experiments. B: Pancreatic islets were isolated from 4- and 14-week-old NOD mice. Islets of 14-week-old animals were cultured for 16 h
to permit the escape of inﬁltrating lymphocytes. RNA was then separately extracted from the islets and the lymphocytes. The levels of miR-29a/b/c
were measured by qRT-PCR, expressed as the percentage of U6 expression and are shown as mean6 SEM of four independent experiments. *P< 0.05 vs.
controls.
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paraformaldehyde, acetylated, and processed for in situ hybridization (21) of
miR-29s and miR-142-3p, using 10 nmol/L 39-digoxygenin-labeled LNA-oligo
probes (Exiqon; mmu-miR29a, MIMAT 0000535; mmu-MiR29b, MIMAT
0000127; mmu-MiR29c, MIMAT 0000577; mmu-miR-142-3p, MIMAT 0000155).
Sections from three mice of each age were analyzed.
Adjacent sections were processed for indirect immunoﬂuorescence staining
(22) of insulin, using sheep polyclonal antibodies (Ventrex, 675), diluted 1:700;
CD8a, using rat monoclonal antibodies (BD Pharmingen, 553028), diluted
1:200; granuphilin, using a rabbit polyclonal, diluted 1:250 (23); and Mcl1,
using a rabbit polyclonal (Santa Cruz Biotechnology, Santa Cruz, CA), diluted
1:250. Incubations were performed for 2 h at room temperature (insulin,
Granuphilin, Mcl1) or for 18 h at 4°C (CD8a). The sections were washed,
exposed for 1 h to ﬂuoresceinated antibodies against sheep, rat, or rabbit IgGs,
counterstained with 0.03% Evans’ blue, and photographed with an Axiophot
ﬂuorescence microscope (22).
Analysis of the expression of protein-coding genes. Total RNA extraction
was performed with the RNeasy mini kit (Qiagen, Hilden, Germany). Conven-
tional quantitative (q)RT-PCR was done as described (24). Real-time PCR
reactions were performed on a Bio-Rad MyiQ Single-Color Real-Time PCR
Detection System (Bio-Rad Laboratories, Hercules, CA) using the following
primers: Proinsulin, sense 59-TGG CTT CTT CTA CAC ACC CA-39 and antisense
59-TCT AGT TGC AGT AGT TCT CCA-39; 18S sense 59-TTT CGC TCT GGT CCG
TCT TG-39 and antisense 59-TTC GGA ACT GAG GCC ATG AT-39; and Mcl1 59-
AGA AAT GTG CTG GCT TT-39. Samples were tested in triplicates and the
results normalized using cDNA ampliﬁed with 18S primers in the same samples.
Modulation of miR-29 level and activity. To increase miRNA levels, MIN6
and primary islet cells were transiently transfected with RNA duplexes
(Eurogentec, Seraing, BE) corresponding to the mature sequence of the
noncoding RNA. Transient transfections of MIN6 cells and islet cells were
performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. For a 24-well plate, 60 pmol/well oligonucleotide
duplexes were used. The transfection efﬁciency in MIN6 cells and dissociated
islet cells evaluated with different anti-miRs and small interfering RNAs
ranged between 70 and 80%. An oligonucleotide duplex corresponding to the
green ﬂuorescent protein (GFP) sequence (59-GAC GUA AAC GGC CAC AAG
UUC-39) was used as control. Transfection of this oligonucleotide does not
affect insulin content and insulin release (Supplementary Fig. 1). Transfection
of the cells with small interfering GFP (or with any other control oligonucle-
otide duplex) increased by about 1% the fraction of cells undergoing apoptosis
compared with untreated cells.
To reduce the level of miR-29, the cells were transiently transfected with an
LNA miRNA inhibitor, whose sequence is 59-CCG ATT TCA AAT GGT GCT-39
(Exiqon, Vedbaek, Denmark). To selectively prevent the binding of miR-29 to
Mcl1 mRNA, without interfering with the action of the miRNA on other targets,
we used a miScript Target Protector speciﬁcally designed for this purpose
(Qiagen, Hilden, Germany) (25). The miScript Target Protector was transiently
transfected in MIN6 cells with Lipofectamine 2000. The results were compared
with those obtained with the Negative Control miScript Target Protector
(Qiagen, Hilden, Germany).
Secretion assay. For the assessment of the secretory capacity, MIN6 cells (23
105) and dissociated mouse and human islet cells (4 3 104) plated in 24- and
96-well dishes, respectively, were transiently cotransfected with oligonucleo-
tides corresponding to the mature miRNA sequences. After 48 h, the cells were
washed and preincubated for 30 min in Krebs buffer (127 mmol/L NaCl,
4.7mmol/L KCl, 1 mmol/L CaCl2, 1.2 mmol/L KH2PO4, 1.2 mmol/L MgSO4,
5 mmol/L NaHCO3, 0.1% BSA, and 25 mmol/L HEPES, pH 7.4) containing
2 mmol/L glucose. The medium was discarded, and the cells were incubated
45 min in the same buffer (basal condition) or in a Krebs buffer containing
20 mmol/L glucose (stimulatory condition). After supernatants were collected,
the cells were lysed in 75% ethanol and 0.55% HCl to evaluate total insulin
content. The amount of insulin in the samples was assessed by ELISA (SPI-bio,
Montigny-le-Bretonneux, France).
Luciferase assay. The Mcl1 39UTR construct was generated by inserting
29 nucleotides of the 39UTR of human Mcl1 (CAGGCTAGTCTAACCATGGTGC
TATTATA) corresponding to the binding sites of miR-29/a/b/c (in bold)
between the SacI and MluI sites of pMir-Report (Ambion) (26). The mutant
construct contained the same sequence except for a G-to-C replacement at
position 21. Luciferase activities were measured with the dual-luciferase
FIG. 2. Proinﬂammatory cytokines increase miR-29 expression. A: MIN6 cells were incubated for 30 h in the presence or absence of a cytokine
mixture (Cyt Mix) of IL-1b (0.1 ng/mL; 50 units/mL), plus TNF-a (10 ng/mL; 500 units/mL) and IFN-g (30 ng/mL; 50 units/mL). miR-29a/b/c
were measured by qRT-PCR and normalized to the level of U6. The results are mean 6 SD of four independent experiments. Mouse (B) and
human (C) islets were incubated for 24 h in the presence or absence of the cytokines mixture indicated above. The levels of miR-29a/b/c were
measured by qRT-PCR and normalized to the expression U6. The results are mean 6 SD of three independent experiments. *P < 0.05 vs.
controls.
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reporter assay system (Promega, Madison, WI). The Fireﬂy luciferase activity
was normalized for transfection efﬁciency with the SV40-driven Renilla ac-
tivity generated by the psiCHECK-1 vector (Promega).
Protein extraction and Western blotting. MIN6 cells or dissociated mouse
islet cells were incubated for 15 min on ice in lysis buffer (50 mmol/L Tris-HCl
[pH 7.5], 0.5% Triton X-100, 137.5 mmol/L NaCl, 10% glycerol, 1 mmol/L sodium
vanadate, 50 mmol/L sodium ﬂuoride, 10 mmol/L sodium pyrophosphate,
5 mmol/L EDTA) and Protease Inhibitors Cocktail (Sigma, St. Louis, MO) and
then sonicated. The homogenate was centrifuged at 12,000 rpm for 1 min and
the supernatant collected for further analysis. Fifty micrograms of the protein
extracts were separated on acrylamide gels and transferred on polyvinylidene
ﬂuoride membranes. The membranes were incubated overnight at 4°C with
primary antibodies. Immunoreactive bands were visualized by chemilu-
minescence (Amersham Biosciences) after incubation with horseradish
peroxidase–coupled secondary antibodies for 1 h at room temperature. The
antibodies against Onecut2 (amino acid 36-311) and granuphilin have been
previously described (23,27). The antibody directed against Syntaxin 1a (S0664)
was purchased from Sigma (Buchs, Switzerland), and that against Mcl-1 (sc-819)
was from Santa Cruz Biotechnology. The antibody against actin was from
Chemicon International (Temecula, CA).
Evaluation of the fraction of cells undergoing apoptosis. For the as-
sessment of apoptosis, MIN6 cells (1 3 105) or dissociated islet cells (8 3 104)
were plated in 24-well dishes and transiently transfected with oligonucleo-
tides leading to miRNA overexpression. Apoptosis was assessed 2 days later
by scoring the cells displaying pyknotic nuclei upon Hoechst dye 33342
staining. The experiments were carried out blindly, and at least 800 cells per
condition were analyzed. To distinguish between apoptosis and necrosis, the
cells were seeded on glass coverslips coated with 2 mg/mL poly-L-lysin
(Sigma, Buchs, Switzerland) and 33.2 mg/mL laminin (Invitrogen, Basel,
Switzerland). Cells undergoing apoptosis or necrosis were identiﬁed using
the Annexin V-EGFP Apoptosis Kit (Biovision, Mountain View, CA) 72 h after
the transfection.
Statistical analysis. Statistical differences were tested by ANOVA. The
experiments including more than two groups were ﬁrst analyzed by ANOVA,
andmultiple comparisons of themeans were then carried out using the post hoc
Dunnett test, with a discriminating P value of 0.05.
RESULTS
We compared the global miRNA expression proﬁle of
pancreatic islets of 4- and 8-week-old NOD mice. In
agreement with our previous ﬁndings (11), the islets of
8-week-old mice displayed an increase in the expression of
miR-21, mir-34a, and miR-146a/b (Supplementary Table 1).
In addition, we detected signiﬁcant alterations in the level
of several other miRNAs, including miR-142-3p, miR-142-5p,
miR-150, miR-155, and miR-216a, which are almost unde-
tectable in the islets of 4-week-old NOD mice (Supple-
mentary Fig. 2 and 3). Because these miRNAs are expected
to be particularly abundant in immune cells (28), their
expression was evaluated in islets of 14-week-old, pre-
diabetic NOD mice, which were cultured to allow for the
escaping of the inﬁltrated lymphocytes (29). These miRNAs
were 100- to 1,000-fold more abundant in the immune cells
that had escaped the islets than in islet cells (Supple-
mentary Fig. 3). In situ hybridization combined with im-
munoﬂuorescence staining for insulin and CD8a (the
hybridization and the immunostaining were performed on
sequential sections of the very same pancreases), conﬁrmed
that most of the miR-142-3p is expressed in immune cells
and not in insulin-producing cells (Supplementary Fig. 4,
top panels). We concluded that the increase in the latter
miRNA in the islet preparations of aging NOD animals likely
reﬂected mainly the presence of immune cells; for this
reason, this group of miRNAs was not investigated any
further in this study.
Among the several other miRNAs that were differen-
tially expressed between 4- and 8-week-old animals, we
noticed the members of the miR-29 family (miR-29a/b/c)
that are among the most abundant miRNAs present
in normal b-cells (30) (Supplementary Table 1). These
miRNAs have been shown to downregulate the expression
of the b-cell disallowed gene, monocarboxylase trans-
porter 1 (31,32) and to contribute to insulin resistance in
insulin target tissues in GK rats (33). Analysis by qPCR
conﬁrmed upregulation of miR-29a/b/c in the islets of
8-week-old mice and revealed a further increase in islet
preparations of normoglycemic 13- to 14-week-old mice
(Fig. 1A). The level of expression of miR-29a/b/c in lym-
phocytes escaping the islets of NOD mice was comparable
to the level detected in the islets of 4-week-old mice (Fig.
1B). Moreover, islets of 14-week-old mice incubated for 24
h to permit the escape of inﬁltrating lymphocytes retained
strongly elevated levels of miR-29a/b/c (Fig. 1B). In
agreement with these observations, in situ hybridization
of NOD pancreas at different ages, combined with an
immunoﬂuorescence staining for insulin on close by sec-
tions, conﬁrmed that the bulk of miR-29a (Supplementary
Fig. 4, lower panels, and Supplementary Fig. 5) and miR-29b
(not shown) is concentrated in insulin-producing cells and
not in inﬁltrating immune cells.
Taken together, these ﬁndings indicate that the rise of
miR-29a/b/c reﬂects changes occurring in b-cells and is not
merely the result of the presence of immune cells in the
islets. The observed increase in miR-29 expression is also
not the result of mice aging. Indeed, miR-29a/b/c levels
FIG. 3. miR-29 overexpression does not change insulin content. A: MIN6
were transfected with a control RNA duplex or with duplexes corre-
sponding to the mature forms of miR-29a, miR-29b, and miR-29c. Pro-
insulin mRNA levels were measured 2 days later by qPCR. Results are
expressed as the ratios between proinsulin and 18S mRNA and shown
as mean 6 SD of four independent experiments. *P < 0.05 vs. controls.
B: Under these conditions, the insulin content of MIN6 cells, as de-
termined by enzyme-linked immunosorbent assay, was not signiﬁcantly
altered. The data shown represent the mean6 SD of seven independent
experiments.
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were not signiﬁcantly different between the islets of 6- and
12-week-old C57BL/6 mice (data not shown), and no sig-
niﬁcant changes were observed in the islets of 13-week-old
NOD-SCID mice that do not develop type 1 diabetes. In
contrast, proinsulin 2-deﬁcient mice, which display accel-
erated insulitis and diabetes (34), showed a dramatic rise
in miR-29a/b/c expression already at age 8 weeks (Sup-
plementary Fig. 6).
Incubation of MIN6 cells (Fig. 2A), mouse islets (Fig. 2B),
or dissociated human islet cells (Fig. 2C) in the presence
of Il-1b (0.1 ng/mL; 50 units/mL), TNF-a (10 ng/mL; 500
unit/mL), and IFN-g (30 ng/mL; 50 units/mL) led to a two-
fold increase in the expression of the three miR-29 family
members, suggesting that at least part of the observed in-
duction occurring during early stages of diabetes devel-
opment in NOD mice was linked to the chronic exposure
of b-cells to these proinﬂammatory cytokines.
To test the effect of miR-29a/b/c overexpression on
pancreatic b-cell functions, oligonucleotides mimicking
the mature sequence of each of the miR-29 family mem-
bers were transiently transfected into MIN6 cells. This
transfection resulted in a cellular content of the respective
miRNA, which was comparable to that observed in the
islets of 8-week-old NOD mice (Supplementary Fig. 7). We
ﬁrst assessed the effect of alterations in the level of the
three miRNAs on insulin biosynthesis. Overexpression of
miR-29 family members led to a small decrease in proinsulin
mRNA levels but did not signiﬁcantly modify total insulin
content (Fig. 3). We then investigated the effects on insulin
release. The rise of miR-29a/b/c in MIN6 cells did not affect
basal insulin secretion (Fig. 4A). In contrast, glucose-induced
insulin release was decreased by 20–40%. A similar reduction
in insulin secretion elicited in the presence of glucose was
detected upon overexpression of miR-29 family members in
primary mouse islet cells (Fig. 4B) and in primary human
islet cells (Supplementary Fig. 8).
The transcription factor Onecut2 is a predicted target of
miR-29a/b/c (http://www.targetscan.org) (35). We previ-
ously demonstrated that Onecut2 modulates the expres-
sion of granuphilin, a secretory granule protein acting as
a potent inhibitor of insulin exocytosis (8) that is ex-
pressed in all b-cells of nondamaged islets, irrespective
of the age of NOD mice (data not shown). In agreement
with the computational predictions, transfections under
the conditions that led to miR-29a/b/c overexpression
resulted in a decrease in the level of Onecut2 and a con-
sequent rise in the expression of granuphilin (Fig. 5) in
MIN6 cells and in dissociated mouse islet cells, poten-
tially explaining at least part of the effect of miR-29 family
members on glucose-induced insulin release. In con-
trast, we were unable to detect signiﬁcant changes in the
level of Syntaxin 1a, a key component of the machinery of
insulin exocytosis (36,37), which is also identiﬁed by
computational programs as a potential target of miR-29
(Fig. 5).
The effect of elevated levels of miR-29 family members
on cell survival was next investigated. Overexpression of
miR-29a/b/c in MIN6 cells (Fig. 6A, left panel) and in
mouse (Fig. 6B, left panel) and human dissociated islet
cells (Fig. 6C) led to a signiﬁcant increase in cell death, as
assessed by scoring the cells displaying pyknotic nuclei.
FIG. 4. miR-29 overexpression alters glucose-induced insulin secre-
tion. A: MIN6 cells were transiently transfected with a control RNA
duplex or with duplexes corresponding to the mature forms of miR-29a,
miR-29b, and miR-29c. Two days later, the cells were incubated in the
presence of 2 or 20 mmol/L glucose (Glc) for 45 min. The amount of
insulin secreted during the incubation period was assessed by enzyme-
linked immunosorbent assay (ELISA). Values were expressed as
percentage of insulin content and are shown as mean 6 SD of ﬁve
independent experiments. B: Cells dispersed from mouse pancreatic
islets were plated and transfected with a control small interfering RNA or
with the indicated oligonucleotide duplexes. Three days later, the cells
were incubated in the presence of 2 or 20 mmol/L glucose for 45 min. The
amount of insulin secreted during the incubation period was assessed by
ELISA. Values were expressed as the percentage of insulin content and
are shown as the mean 6 SD of three independent experiments. Total
insulin content was 16 6 4, 18 6 5, 16 6 4, and 16 6 5 for control, miR-
29a, b, and c, respectively. *P < 0.05 vs. control cells stimulated with
20 mmol/L glucose.
FIG. 5. Overexpression of miR-29 selectively alters the expression of
proteins involved in insulin exocytosis. MIN6 cells (left panel) or dis-
sociated mouse islet cells (right panel) were transiently transfected
with RNA duplexes that allow for overexpression of miR-29a, b, or c.
Western blotting showed that this change was associated to a reduction
in the levels of Onecut2 and to an increase in the levels of granuphilin,
without alterations of Syntaxin 1a. A representative of three to ﬁve
experiments is shown.
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Identical results were obtained when apoptosis was
assessed by Annexin V labeling (Fig. 6A and B, right panels).
In contrast, the number of necrotic cells determined by
propidium iodide labeling remained unchanged (data not
shown). Pretreatment with anti–miR-29c signiﬁcantly de-
creased, to control levels, the number of MIN6 cells un-
dergoing apoptosis in the presence of IL-1b, TNF-a, and
IFN-g (Fig. 6D).
We then attempted to elucidate the mechanisms through
which a rise in the level of miR-29a/b/c can trigger b-cell
death. Interestingly, Mcl1, an antiapoptotic protein be-
longing to the Bcl2 family and playing a key role in b-cell
survival (38), is a predicted target of miR-29a/b/c (26,39).
Indeed, we found that increased levels of miR-29a/b/c
inhibited the expression by MIN6 cells of a luciferase
construct containing the 39UTR sequence of Mcl1 (Fig. 7A).
This effect was abrogated by mutation of the sequence
recognized by these miRNAs, indicating a direct interaction
with the 39UTR of Mcl1. Western blot analysis con-
ﬁrmed a signiﬁcant reduction of the level of Mcl1 in
MIN6 cells and in mouse islet cells overexpressing the
miR-29 family members (Fig. 7B and C). No signiﬁcant
changes in MCL1 mRNA levels were detected in miR-29
overexpressing cells, indicating that the effect of the
miRNAs is mainly post-transcriptional (Supplementary
Fig. 9).
FIG. 6. Overexpression of miR-29 increases the apoptosis of transformed and primary b-cells. A: MIN6 cells were transiently transfected with
a control RNA duplex or with duplexes leading to miR-29a, miR-29b, and miR-29c overexpression. Three days later, the monolayers were stained
with Hoechst dye 33342 to score for dead cells (left panel) or with Annexin V–enhanced green ﬂuorescent protein (EGFP) to score for apoptotic
cells (right panel). B: Islet cells were dispersed from mouse islets and plated. Adherent cells were transfected with the indicated duplexes. Three
days later, the monolayers were stained with Hoechst dye 33342 (left panel) or with Annexin V-EGFP (right panel). C: Dissociated human islet
cells were transfected with a control RNA duplex or with duplexes leading to miR-29a, miR-29b, and miR-29c overexpression. Three days later, the
monolayers were stained with Hoechst dye 33342 to score for cells displaying pyknotic nuclei. D: MIN6 cells were transfected with a control
oligonucleotide or with a modiﬁed antisense oligonucleotide that speciﬁcally inhibits miR-29c (anti–miR-29c). The day after, the cells were in-
cubated with or without IL-1b (0.1 ng/mL) plus TNF-a (10 ng/mL) and IFN-g (30 ng/mL), and 24 h later, the glass coverslips cells were stained with
Annexin V-EGFP to score the fraction of apoptotic cells. All ﬁgures show the mean 6 SD of three (B and C) to ﬁve (A) independent experiments.
*P < 0.05 vs. control.
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To demonstrate a direct link between the reduction of
Mcl1 and the effect of miR-29 on b-cell apoptosis, MIN6
cells were transfected with an oligonucleotide designed to
speciﬁcally protect the Mcl1 mRNA from miR-29 binding,
without interfering with the regulation of other miR-29
targets (25). The reduction in Mcl1 levels elicited by miR-
29c overexpression or by proinﬂammatory cytokines was
efﬁciently prevented by transfection of this target protector
(Supplementary Fig. 10A and B). As shown in Fig. 8A, the
cells expressing the Mcl1 target protector were resistant to
apoptosis induced by miR-29 overexpression. Moreover, the
cells transfected with the Mcl1 target protector were not
sensitive to cytokine-induced apoptosis (Fig. 8B), indi-
cating that at least part of the deleterious effect of these
inﬂammatory mediators on b-cell survival is caused by a miR-
29–induced drop in the expression of the antiapoptotic Mc11
protein.
DISCUSSION
During the initial phases of type 1 diabetes, pancreatic
b-cells are chronically exposed to inﬂammatory mediators
released by immune cells invading the islets of Langerhans.
This results in major changes in gene expression, with
consequent defects in the accomplishment of specialized
functions, and loss of the cells by apoptosis (1). We re-
cently demonstrated that part of the changes in gene ex-
pression triggered by proinﬂammatory cytokines reﬂects
alterations in the level of a new class of regulatory mole-
cules, the miRNAs (11). Indeed, we found that prolonged
exposure to IL-1b or TNF-a results in a strong upregula-
tion of miR-21, miR-34a, and miR-146a, with large effects
on the secretory capacities of b-cells and their sensitivity to
apoptosis (11). In this study, we conﬁrm these ﬁndings and
further extend them via the identiﬁcation of additional
miRNAs, whose expression level is markedly altered with
the onset of type 1 diabetes in NOD mice. The members of
the miR-29 family, which are among the most abundant
miRNAs expressed in mouse pancreatic b-cell (11,30), in-
creased with the age of prediabetic but still normoglycemic
NOD mice. In situ hybridization and qPCR analysis, coupled
with immunoﬂuorescence for insulin, demonstrated that the
rise in miR-29 expression occurred in b-cells and not in in-
vading immune cells.
The mechanism responsible for this induction of miR-
29a/b/c in NOD mice remains to be fully elucidated. We
found that exposure of MIN6 cells and human islets to
proinﬂammatory cytokines causes a twofold increase in
FIG. 7. Mcl1 is a direct target of miR-29 family members. A: MIN6 cells were cotransfected with a Renilla luciferase construct and Fireﬂy luciferase
reporter plasmids containing the wild-type (wt) or a mutated (mut) sequence of the 39UTR of mouse Mcl1 and RNA duplexes, leading to miR-29a,
miR-29b, or miR-29c overexpression. Luciferase activities were measured 3 days later. Fireﬂy luciferase activities were divided by the Renilla
luciferase activities to correct for differences in transfection efﬁciency. The value obtained under control condition was set to 100%. Values are
mean 6 SD of four independent experiments. B: MIN6 cells (left panel) or dissociated mouse islet cells (right panel) were transfected with the
indicated duplexes. Expression of Mcl1 and actin was assessed by Western blotting. A representative of three experiments is shown. C: Quanti-
ﬁcation of the effect of miR-29a/b/c overexpression on Mcl1 expression by densitometric scanning of the ﬁlms in MIN6 cells (left panel) and mouse
islets (right panel). The results are expressed as means 6 SD of three independent experiments. *P < 0.05 vs. control.
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the expression of miR-29 family members. These results
are in good agreement with those obtained previously by
microarray analyses (11). The signaling pathways involved
in the induction of miR-29 family members have not been
dissected yet. Zhou et al. (40) have recently identiﬁed in
the promoter of miR-29a potential binding sites for NFkB,
a transcription factor known to contribute to cytokine-
mediated b-cell dysfunction and to the development of
type 1 diabetes (41). Expression of miR-29 was also re-
ported to be modulated by p53 (42), a transcription fac-
tor that is induced in response to proinﬂammatory
cytokines (43) and that we have shown controls the ex-
pression of other miRNAs (7). Additional cytokines, such
as IL-4 and TGF-b, which are defectively produced in
NOD mice (44–46), have been reported to inhibit miR-29
expression in other cell systems (47). A deﬁcit of these
cytokines may potentially contribute to the strong upre-
gulation of miR-29a/b/c that is observed in the islets of
prediabetic NOD mice.
Our results demonstrate that miR-29 overexpression
downregulates glucose-induced insulin secretion of pri-
mary mouse and human islet cells as well as of MIN6 cells.
This downregulation is associated with the interaction of the
miRNAs with Onecut2, one of their putative targets. This
transcription factor controls the expression of granuphilin/
Sytl-4 (8), a Rab guanine triphosphate (GTP)ase effector
that colocalizes with the dense-core, insulin-containing
granules of pancreatic b-cells and acts as a potent inhibitor
of insulin exocytosis (23,48). Thus, by decreasing Onecut2
levels, miR-29 enables the expression of increased amounts
of granuphilin, resulting in impaired stimulation of insulin
secretion. Consistent with this mechanism, we found that
granuphilin is abundant in most b-cells, irrespective of the
age of the NOD mice, and the presence of peri- or intraislet
insulitis.
Prolonged exposure to proinﬂammatory cytokines is
known to affect b-cell survival. Overexpression of miR-29a,
-b, or -c to levels comparable to those observed in 8-week-old
NOD mice mimics the effect of the cytokines. Moreover,
blockade of miR-29 protects b-cells from the deleterious
effect of these inﬂammatory mediators. In line with results
obtained in other cell types (26,39,49), Western blot anal-
ysis and luciferase reporter assays demonstrated a de-
crease in the level of the antiapoptotic protein Mcl1 on
miR-29 overexpression. Downregulation of this antiapoptotic
protein is a crucial event, leading to b-cell apoptosis in
response to cytokines (38). Our data are in good agree-
ment with these observations and suggest that, as it is the
case in other cell systems, even a modest reduction of
Mcl1 levels caused by miR-29 overexpression can result in
loss of mitochondrial potential, cytochrome c release, and
activation of caspase-3 (39). Indeed, an oligonucleotide
speciﬁcally designed to mask the binding site of miR-29 on
Mcl1 39UTR, without affecting the stability or the trans-
lation of the mRNA (25), restored the expression of the
antiapoptotic protein, and prevented both miR-29– and
cytokine-mediated apoptosis. Our ﬁndings suggest that
molecules capable of protecting individual targets rep-
resent attractive tools to precisely dissect the mode of
action of miRNAs and could also serve as therapeutic
strategies to selectively promote the expression of single
genes beneﬁcial for b-cells.
The miR-29 family members have been shown to con-
tribute to insulin resistance in insulin target tissues of GK
rats (33). Interestingly, type 1 diabetes in NOD mice is
associated with insulin resistance (50). Moreover, miR-29
FIG. 8. miR-29– and cytokine-induced apoptosis is blocked by preventing binding to Mcl1. A: MIN6 cells were transfected with a control RNA duplex
or with duplexes corresponding to the mature form of miR-29c, together with a scrambled miScript Target Protector as a negative control or a Mcl1
miScript Target Protector. Three days after transfection, the cells were stained with Annexin V–enhanced green ﬂuorescent protein (EGFP) to
score the fraction of apoptotic cells. B: MIN6 cells were transfected with the scrambled miScript Target Protector as a negative control or with the
Mcl1 miScript Target Protector. Two days later, the cells were treated for 24 h with a mix of cytokines (Cyt Mix) including IL-1b (0.1 ng/mL), TNF-a
(10 ng/mL), and IFN-g (30 ng/mL). At the end of the incubation, the cells were stained with Annexin V-EGFP to score the fraction of apoptotic cells.
All ﬁgures show the mean 6 SD of three independent experiments. *P < 0.05 vs. control.
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has recently been reported to inhibit innate and adaptive
immune responses by suppressing the production of
IFN-g in natural killer cells and T lymphocytes (51). Thus,
changes in miR-29 expression may play a broader role in
the pathogenesis of type 1 diabetes.
The current study was carried out in NOD mice, an an-
imal model sharing many characteristics of type 1 diabetes
in humans and that has signiﬁcantly contributed to our
understanding of the molecular processes associated with
the development of this disease (52). It will now be im-
portant to conﬁrm that the mechanisms identiﬁed in NOD
mice and b-cell lines are indeed also operating during the
initial phases of type 1 diabetes in humans. Should this
turn out to be the case, a better knowledge of islet miRNA
dysfunction may open the way to alternative strategies to
delay and prevent the development of the disease in newly
diagnosed type 1 diabetic patients.
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